Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.
Since the late 1970s a number of laboratories have studied the role of vasoactive intestinal peptide (VIP) in inflammation and immunity. These studies have highlighted the dramatic effect of VIP on immune cell activation and function, and studies using animal models of disease have indicated that VIP has significant therapeutic and prophylactic potential. This review will focus on the effects of VIP on innate immune cell function and discuss the therapeutic potential for VIP in inflammatory diseases of humans.
Smalley
S G R
SG
School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Sutton Bonington, Leicestershire, UK.
Barrow
P A
PA
Foster
N
N
D016207:Cytokines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D007113:Immunity, Innate; D018836:Inflammation Mediators / Q000378:metabolism; D018005:Receptors, Vasoactive Intestinal Peptide / Q000378:metabolism; D051193:Toll-Like Receptors / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000502:physiology* / Q000627:therapeutic use
D016207:Cytokines; D018836:Inflammation Mediators; D018005:Receptors, Vasoactive Intestinal Peptide; D051193:Toll-Like Receptors; D014660:Vasoactive Intestinal Peptide